statistiche ricercatore

Continente	#
EU - Europa	896
NA - Nord America	880
AS - Asia	581
SA - Sud America	59
AF - Africa	22
Continente sconosciuto - Info sul continente non disponibili	2
Totale	2.440

Nazione	#
US - Stati Uniti d'America	861
RU - Federazione Russa	320
GB - Regno Unito	240
SG - Singapore	222
CN - Cina	180
SE - Svezia	72
IT - Italia	63
DE - Germania	53
VN - Vietnam	53
HK - Hong Kong	46
IE - Irlanda	44
BR - Brasile	41
FR - Francia	36
FI - Finlandia	27
KR - Corea	15
IN - India	14
CA - Canada	9
MX - Messico	9
NL - Olanda	9
TR - Turchia	9
BD - Bangladesh	8
JP - Giappone	7
ZA - Sudafrica	7
AR - Argentina	5
ES - Italia	5
LT - Lituania	5
PH - Filippine	5
ID - Indonesia	4
PK - Pakistan	4
PL - Polonia	4
UA - Ucraina	4
VE - Venezuela	4
BE - Belgio	3
CH - Svizzera	3
MA - Marocco	3
PY - Paraguay	3
RO - Romania	3
SN - Senegal	3
CZ - Repubblica Ceca	2
EC - Ecuador	2
EU - Europa	2
IQ - Iraq	2
KE - Kenya	2
LK - Sri Lanka	2
LY - Libia	2
MY - Malesia	2
SY - Repubblica araba siriana	2
AE - Emirati Arabi Uniti	1
AF - Afghanistan, Repubblica islamica di	1
AL - Albania	1
AT - Austria	1
AZ - Azerbaigian	1
BO - Bolivia	1
CI - Costa d'Avorio	1
CL - Cile	1
CO - Colombia	1
CY - Cipro	1
EG - Egitto	1
GR - Grecia	1
JO - Giordania	1
KG - Kirghizistan	1
MW - Malawi	1
NG - Nigeria	1
SR - Suriname	1
SV - El Salvador	1
TN - Tunisia	1
Totale	2.440

Nome	#
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases	229
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies	209
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma	194
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer	191
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials	185
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?	185
AR-V7 and prostate cancer: The watershed for treatment selection?	178
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?	177
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder	174
The route to personalized medicine in bladder cancer: where do we stand?	162
Metabolic alterations in renal cell carcinoma	160
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice	149
Metabolic Alterations in Renal and Prostate Cancer	146
Kidney cancer and 2014: is innovation really over?	128
Totale	2.467

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	13	0	0	0	0	0	0	0	0	0	1	6	6
2021/2022	97	8	17	0	18	8	5	2	4	6	0	4	25
2022/2023	278	18	33	23	49	23	67	0	26	29	2	7	1
2023/2024	102	6	6	10	10	23	9	2	11	3	3	18	1
2024/2025	323	17	20	26	80	5	15	7	8	54	9	27	55
2025/2026	1.055	69	44	65	228	293	88	78	51	79	60	0	0
Totale													2.467

CATALOGO DEI PRODOTTI DELLA RICERCA